Induction of Broad-Based Immunity and Protective Efficacy by Self-amplifying mRNA Vaccines Encoding Influenza Virus Hemagglutinin

Michela Brazzoli, Diletta Magini, Alessandra Bonci, Scilla Buccato, Cinzia Giovani, Roland Kratzer, Vanessa Zurli, Simona Mangiavacchi, Daniele Casini, Luis M. Brito, Ennio De Gregorio, Peter W. Mason, Jeffrey B. Ulmer, Andrew J. Geall, Sylvie Bertholet
  • Journal of Virology, October 2015, ASM Journals
  • DOI: 10.1128/jvi.01786-15

Why is it important?

The rapid production capacity and the synthetic origin of the vaccine make this platform particularly exploitable in case of an influenza pandemic.

Perspectives

Dr Sylvie Bertholet (Author)
GSK Vaccines US

If the SAM vaccine platform proves safe, well tolerated, and effective in humans, the fully synthetic SAM vaccine technology could provide a rapid response platform to control pandemic influenza.

The following have contributed to this page: Dr Sylvie Bertholet

In partnership with: